Latest News
The data of the Phase 3 international multicenter clinical trial and the mechanism of action of Fespixon (ON101) have been published by JAMA Network Open

Source: Oneness Biotech

Fespixon (research code: ON101) has demonstrated clinical superiority in the healing of the diabetic foot ulcers in the Phase 3 international multicenter clinical trial. The clinical data and its unique mechanism of action have been submitted to the JAMA Network Open, a medical journal published by the American Medical Association, and has been accepted for publication on September 3rd 2021.
The publication of Fespixon’s Phase 3 data and mechanism of action is an acknowledgement by the JAMA Network Open on its clinical and scientific evidence. The open access online will increase the understanding of Fespixon’s efficacy by the international diabetic foot ulcer (DFU) specialists and also raise the global profile of the new drug. It is hoped that this will benefit the global DFU patients. More details please refer to the link below. 

Effect of a Novel Macrophage-Regulating Drug on Wound Healing in Patients With Diabetic Foot Ulcers- A Randomized Clinical Trial

Information appearing on this website (images and texts, unless otherwise indicated) is the property of IBMI. To use or share, please indicate the source.
©Institute for Biotechnology and Medicine Industry (IBMI) All rights reserved.
Address:16F.-1, No.3, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.) Contact Number:(02)2655-8168 Fax:(02)2655-7978